

HOUSE BILL No. 2157

By Committee on Health and Human Services

Requested by Heather Sprague on behalf of the Kansas Association of Chain Drugstores

1-29

1 AN ACT concerning pharmacists and pharmacy; relating to the state board
2 of pharmacy; expanding the pharmacist's scope of practice to include
3 point-of-care testing for and treatment of COVID-19; amending K.S.A.
4 2024 Supp. 65-16,131 and repealing the existing section.
5

6 *Be it enacted by the Legislature of the State of Kansas:*

7 Section 1. K.S.A. 2024 Supp. 65-16,131 is hereby amended to read as
8 follows: 65-16,131. (a) A pharmacist may initiate therapy within the
9 framework of a statewide protocol for the following health conditions:

- 10 (1) Influenza;
- 11 (2) streptococcal pharyngitis; ~~or~~
- 12 (3) urinary tract infection; *or*
- 13 (4) *COVID-19*.

14 (b) The collaborative drug therapy management advisory committee
15 established pursuant to K.S.A. 65-1677, and amendments thereto, may
16 adopt a statewide protocol for each condition listed in subsection (a). In
17 establishing such statewide protocols, the committee shall specify:

- 18 (1) The medications or categories of medications included in the
19 protocol for each health condition;
- 20 (2) the training or qualifications required for pharmacists to
21 implement the protocols;
- 22 (3) requirements for documentation and maintenance of records,
23 including patient inclusion and exclusion criteria, medical referral criteria,
24 patient assessment tools based on current clinical guidelines, follow-up
25 monitoring or care plans and the pharmacist's adherence to the applicable
26 protocols; and
- 27 (4) communication requirements, including, but not limited to,
28 notification to the patient's personal or primary care provider.

29 (c) The board may deny an application or renewal or revoke or
30 suspend the license of a pharmacist upon a finding that the pharmacist has
31 violated the provisions of this section or failed to practice within the
32 framework of statewide protocols established pursuant to this section by
33 the collaborative drug therapy management advisory committee.

- 34 ~~(d) This section shall take effect and be in force on and after July 1,~~

1 ~~2022.~~

2 Sec. 2. K.S.A. 2024 Supp. 65-16,131 is hereby repealed.

3 Sec. 3. This act shall take effect and be in force from and after its

4 publication in the statute book.